Insurers Brace For Pfizer’s $225K Heart Drug And Whether To Pay For It

It’s unclear whether health insurers and PBMs will cover Pfizer’s $225,000 a year drug tafamidis to treat a rare heart disease.

Read the full post on Forbes - Healthcare